In a patient with minimal coronary plaque (CAD‑RADS 1) showing a punctate calcified focus at the ostium of the left anterior descending artery without stenosis, no plaque in the left main, left circumflex, or right coronary arteries, and a mildly dilated ascending aorta measuring 3.9 × 3.8 cm, what further evaluation or medical management is indicated?

Medical Management with Surveillance Imaging for Ascending Aorta

For this patient with CAD-RADS 1 and a mildly dilated ascending aorta measuring 3.9 × 3.8 cm, initiate aggressive medical management for coronary atherosclerosis and establish surveillance imaging for the ascending aorta with repeat imaging in 1-2 years.

Coronary Artery Disease Management (CAD-RADS 1)

Your patient has minimal coronary plaque burden with a CAD-RADS 1 classification, which represents minimal non-obstructive disease. While this carries a favorable prognosis, the presence of any coronary atherosclerosis warrants aggressive risk factor modification 1.

Medical Management Strategy:

• Statin therapy: Initiate moderate-to-high intensity statin regardless of LDL level, as any detectable plaque indicates atherosclerotic disease requiring treatment
• Antiplatelet therapy: Consider low-dose aspirin (81-100 mg daily) if not contraindicated, particularly given the presence of calcified plaque
• Blood pressure control: Target <130/80 mmHg if hypertensive
• Glycemic control: If diabetic, optimize HbA1c to <7%
• Lifestyle modification: Smoking cessation (if applicable), Mediterranean diet, regular aerobic exercise

The "power of zero" concept doesn't apply here—your patient has detectable plaque, which fundamentally changes risk stratification 1. Even minimal plaque indicates the atherosclerotic process has begun and requires intervention.

No Further Cardiac Testing Needed Currently:

CAD-RADS 1 does not warrant functional testing or invasive angiography. The punctate calcified focus at the LAD ostium without stenosis is not hemodynamically significant 2, 3.

Ascending Aorta Management

Your patient's ascending aorta at 3.9 cm is at the threshold of what the 2022 ACC/AHA guidelines define as "dilated." This is clinically significant and requires attention.

Key Guideline Thresholds 4:

• ≥4.0 cm = Dilated aorta (89-fold increased dissection risk vs. ≤3.4 cm)
• ≥4.5 cm = Aneurysm (6,000-fold increased dissection risk)

At 3.9 cm, your patient is just below the formal "dilated" threshold but warrants surveillance given proximity to 4.0 cm.

Surveillance Strategy:

Repeat imaging in 1-2 years with either:

• CT angiography (preferred for precise measurement consistency)
• Transthoracic echocardiography
• Cardiac MRI

Important Considerations:

• Body size adjustment: The 4.0 cm threshold assumes average height/BSA. If your patient is significantly shorter than average, this measurement may be more concerning and warrant closer surveillance (annually) 4
• Underlying conditions: Screen for bicuspid aortic valve, connective tissue disorders (Marfan, Loeys-Dietz), or family history of aortic disease—these would mandate more aggressive surveillance and potentially earlier intervention
• Blood pressure control: Critical for preventing aortic growth—target <130/80 mmHg, consider beta-blockers if there's concern for progression

When to Refer to Cardiothoracic Surgery:

• Growth rate >0.5 cm/year
• Diameter reaches ≥4.5 cm (aneurysm threshold)
• Development of symptoms (chest/back pain)
• If bicuspid aortic valve or genetic syndrome identified (lower thresholds apply)

Common Pitfalls to Avoid:

1. Don't dismiss the 3.9 cm measurement as "normal"—it's borderline and requires follow-up
2. Don't assume CAD-RADS 1 means no treatment needed—any plaque warrants aggressive medical therapy
3. Don't measure the aorta at different anatomic levels on follow-up—ensure consistent measurement location for accurate comparison
4. Don't forget to adjust aortic thresholds for body size in very short or tall patients